Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors

Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors

Abstract Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well demonstrated in most GEP NETs, with the exception o...

Full description

Bibliographic Details
Main Authors: Joo Young Kim, Jisup Kim, Yong-il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Scientific Reports
Subjects:
Somatostatin
Receptor 2
Rectum
Neuroendocrine tumor
Prognosis
Online Access:https://doi.org/10.1038/s41598-024-54599-4

Internet

https://doi.org/10.1038/s41598-024-54599-4

Similar Items